Fixed Bed Culture System for Enterovirus A Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing Enterovirus A, such as EV71, face challenges in achieving high yields due to rapid cell lysis and the need for complex, costly, and contamination-prone processes, particularly in industrial-scale vaccine production.
Innovation Solution
A fixed bed culture system is used for culturing adherent cells with optimized cell densities and media conditions, allowing for efficient production of Enterovirus A, including the use of macrocarriers and specific cell culture mediums to enhance viral production and reduce contamination risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If classical cell culture methods are used for Enterovirus A production, then the process is well-established and easier to operate, but the viral yield is low due to rapid cell lysis and the process is contamination-prone
Solution Approach 1:
The patent introduces a serum-free medium as an intermediary substance that mediates between the virus and host cells, enabling high-yield virus production without contamination from animal-derived sera. This intermediary medium provides necessary nutrients while maintaining sterility and preventing contamination, thereby resolving the contradiction between productivity and reliability
Solution Approach 2:
The patent changes the chemical composition parameters of the culture medium by replacing serum-containing media with serum-free media having specific defined compositions. This parameter change eliminates contamination risks associated with serum while optimizing conditions for high viral yield, thus resolving the contradiction between reliability and productivity
2Reliability
If complex production processes are used to maintain cell viability, then cell survival is improved, but the process becomes more costly and operationally complex
Solution Approach 1:
The serum-free medium is designed to provide all necessary nutrients and growth factors that cells need to survive and produce virus, making the medium self-sufficient rather than requiring complex external supplementation protocols. This self-service approach maintains cell viability while simplifying the overall process, resolving the contradiction between reliability and device complexity
3Ease of operation
If serum-containing media are used for cell culture, then cell growth is supported, but the risk of contamination and operational complexity increases
Solution Approach 1:
The patent employs a defined serum-free medium that can be sterilized and used without the contamination risks associated with animal sera. This disposable-like approach with clearly defined composition eliminates the need for complex serum handling and quality control, reducing contamination risk while maintaining ease of operation through standardized protocols
Data Source
Figure 1
Figure 2A~2C
Figure 3
AI summary
The present disclosure relates to methods of producing Enterovirus A, e.g., for vaccine production, that include culturing cells in a fixed bed bioreactor. Further provided herein is an Enterovirus A produced by the methods of production disclosed herein, as well as compositions, immunogenic compositions, and vaccines related thereto.